If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
=== Bone morphogenetic proteins === Bone morphogenetic proteins (BMPs) are proteins that are made of acidic polypeptides and belongs to the TGF-B family. BMPs promote the regeneration of bone tissue and cartilage. BMP exhibits osteoinductive activity. Osteoinductive activity leads to bone formation, activates mesenchymal cells to transform into osteoblasts which ultimately yield bone formation. BMP targets and binds to mesenchymal cells and activates a transmembrane serine/threonine kinase receptor which will lead to the phosphorylation of molecules called SMADS. SMADS are transcription factors that will induce osteoblast growth.
Anti-vitamins are chemical compounds that inhibit the absorption or actions of vitamins. For example, avidin is a protein in raw egg whites that inhibits the absorption of biotin; it is deactivated by cooking. Pyrithiamine, a synthetic compound, has a molecular structure similar to thiamine, vitamin B1, and inhibits the enzymes that use thiamine.
==== On-screen authority figure (2003–2004) ==== The following month, Linda McMahon brought Austin back to be the co-general manager of the Raw brand, a role he played for the remainder of the year, often getting into physical altercations with talent and personnel. Austin and Bischoff continued to feud over control of the brand. On the July 21 episode of Raw, McMahon informed Austin he could not get physical with anyone unless provoked. At Survivor Series on November 16, Austin's hand-picked team of Booker T, Bubba Ray Dudley, D-Von Dudley, Rob Van Dam and Shawn Michaels faced Bischoff's team of Chris Jericho, Christian, Mark Henry, Randy Orton and Scott Steiner in a 5-on-5 Survivor Series elimination match. Austin's team lost after Batista interfered on behalf of Bischoff. After the match Jonathan Coachman came out to gloat and got beat up by Austin. As a result, Austin was "fired" from his position as co-general manager. Mick Foley took over Austin's former role and began petitioning to have Austin re-instated. Austin returned before the end of 2003, appearing at Tribute to the Troops. He posed as Santa Claus before delivering a "Stone Cold Stunner" to both Vince McMahon and John Cena. Austin returned to Raw on December 29 as its "Sheriff", giving a Stone Cold Stunner to Bischoff and rehiring Michaels, who had just been "fired" by Bischoff. Austin appeared on-and-off as 2004 began, culminating in him being the special guest referee for the Brock Lesnar vs. Goldberg match at WrestleMania XX on March 14.
Asymmetric warfare – Araucanian leaders such as Lautaro developed effective military tactics to counter the Spanish invasion, winning the Arauco War. These tactics consisted in a combination of espionage, cattle raiding, and using attack waves in the battlefield to exhaust the enemy. Astronomy – Mesoamerican cultures, such as the Maya and Aztec, were able to accurately predict astronomical events, like eclipses, hundreds of years into the future. Atlatl – Paleo-Indians (Beringian Diaspora) from over 11,500 years ago had developed a highly developed spear thrower in the form of the atlatl to hunt woolly mammoths, giant sloths, mastodon, muskox (euceratherium), giant beaver, early caribou, steppe bison, saber-toothed cat, and other Pleistocene animals. Using the atlatl, these ancient Paleo-Indians were able to traverse much of the Americas from Alaska, down to Mexico, Central America, South America, and, finally, all the way south into Chile as they hunted and followed these Pleistocene megafauna within a short 3,000 year time period–from about 14,500 years ago to about 11,500 years ago. Avocado – Indigenous Americans were the first to domesticate and cultivate avocados.
Sources: en.wikipedia.org
=== Neuroprotection and DNA repair === Estrogen regulated DNA repair mechanisms in the brain have neuroprotective effects. Estrogen regulates the transcription of DNA base excision repair genes as well as the translocation of the base excision repair enzymes between different subcellular compartments. Estrogen provides neuroprotection by modulating the endocannabinoid system activity, primarily through the regulation of fatty acid amide hydrolase (FAAH) enzyme expression and the endocannabinoid receptor Cβ1 levels. The protective effects appears to work through a fine-tuning mechanism where by estrogen both suppresses excessive endocannabinoid signaling at the Cβ1receptor (which can be neurotoxic under stress) while simultaneously maintaining physiological endocannabinoid tine needed for normal neural function.
Bupropion was invented by Nariman Mehta of Burroughs Wellcome (now GlaxoSmithKline) in 1969, and the US patent for it was granted in 1974. It was approved by the US Food and Drug Administration (FDA) as an antidepressant on 30 December 1985, and marketed under the name Wellbutrin. However, a significant incidence of seizures at the originally recommended dosage (400–600 mg/day) caused the withdrawal of the drug in 1986. Subsequently, the risk of seizures was found to be highly dose-dependent, and bupropion was reintroduced to the market in 1989 with a lower maximum recommended daily dose of 450 mg/day. In 1996, the US Food and Drug Administration (FDA) approved a sustained-release formulation of alcohol-resistant bupropion called Wellbutrin SR, a tablet intended to be taken twice a day (as compared with three times a day for immediate-release Wellbutrin). In 2003, the FDA approved another sustained-release formulation called Wellbutrin XL, a hard-shelled tablet intended for once-daily dosing. Wellbutrin SR and XL are available in generic form in the United States and Canada. In 1997, bupropion was approved by the FDA for use as a smoking cessation aid under the name Zyban. In 2006, Wellbutrin XL was similarly approved as a treatment for seasonal affective disorder. In October 2007, two providers of consumer information on nutritional products and supplements, ConsumerLab.com and The People's Pharmacy, released the results of comparative tests of different brands of bupropion.
Cyclic ADP-ribose, frequently abbreviated as cADPR, is a cyclic adenine nucleotide (like cAMP) with two phosphate groups present on 5' OH of the adenosine (like ADP), further connected to another ribose at the 5' position, which, in turn, closes the cycle by glycosidic bonding to the nitrogen 1 (N1) of the same adenine base (whose position N9 has the glycosidic bond to the other ribose). The N1-glycosidic bond to adenine is what distinguishes cADPR from ADP-ribose (ADPR), the non-cyclic analog. cADPR is produced from nicotinamide adenine dinucleotide (NAD+) by ADP-ribosyl cyclases (EC 3.2.2.5) as part of a second messenger system.
Sources: en.wikipedia.org
== X == Xiaoliang Sunney Xie (born 1962), Chinese-American biochemist, pioneer in the field of Single Molecule Microscopy and CARS (Coherent Anti-Stokes Raman Spectroscopy) microscopy Xie Yi (born 1967), Chinese chemist, member of the Chinese Academy of Sciences and a fellow of the Royal Society of Chemistry.
The condition can cause localized pain, discoloration (paleness), and sensations of cold and/or numbness. When exposed to cold temperatures, the blood supply to the fingers or toes, and in some cases the nose or earlobes, is markedly reduced; the skin turns pale or white (called pallor) and becomes cold and numb. These events are episodic, and when the episode subsides or the area is warmed, the blood flow returns and the skin color first turns red (rubor), and then back to normal, often accompanied by swelling, tingling, and a painful "pins and needles" sensation. All three color changes are observed in classic Raynaud's yet not all patients see all of the aforementioned color changes in all episodes, especially in milder cases of the condition. The red flush is due to reactive hyperemia of the areas deprived of blood flow. In pregnancy, this sign normally disappears due to increased surface blood flow. Raynaud's has occurred in breastfeeding mothers, causing nipples to turn white and painful.
The lawsuit was brought against VPX and its owner for claims of false advertising under the Lanham Act, California laws regarding unfair competition and false advertising, as well as trade libel. The jury issued the verdict on September 29, 2022. Following a trial lasting over a month, the jury awarded Monster Energy $293 million in damages. Among the damages were $272 million awarded for false advertising, $18 million for Bang's interference with contracts, and $3 million for trade secret theft. In October 2023, a judge awarded an additional $43 million dollars to Monster Energy for attorney fees and expenses.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.